Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey S. Mitchell who wrote (2852)	8/15/1998 1:13:00 AM
From: Cavalry	Read Replies (1) \| Respond to of 4028

look what graystone posted on another stock message board!!! This company is what a worthless pump and dump is. The latest hype job they started was centered around the cure for aging. (I am not making any of this up). Having used up the "cure for cancer" story, and the "cure for abortion" story, they did not have anything else to hype. So they made up the "cure for aging" story. The promotion team, as I said, led by Big Dog, is completely unethical and just about the lowest life forms I have ever encountered. Probably the worst is a certain Cavalry. He lies almost as convincingly as Barry R., but not quite. He is trying to get a hundred hypesters to give him a blessing on his SI WHAM thread. He is such a lying little scuzzball that I actually would like to meet him, for the express purpose of cold cocking the baxxxd. Brazen thieves, lying jerks, lowlife sxxm bxgs. Hogger is another pretender, another poseur, a lying sxxxxag posing as a small investor. These guys are ripping off the little guy with the complete blessing of the SI Administration. I can see why many Stockhouse posters do not like going to SI. Over here, you are allowed to defend yourself, over there, responding to allegations gets you kicked off. Previous Message Next Message [ Post New Message ] [ Reply to Message ] [ CYGS Forum Menu ] [ Main Forum Menu ] Link to this message externally: jeffrey is this man a friend of yours? had to xxxx several words, hope si bob leaves this post up so people can see the anger in someone who isn't long or short a stock, scarey man, imo

To: Jeffrey S. Mitchell who wrote (2852)	8/15/1998 2:53:00 PM
From: LANCE B	Read Replies (3) \| Respond to of 4028

hey jeff,one to go over something else i found today........now janice and everyone has been questioning mike skillern past and whether there is anything else going on.........i saw a release today that was 10 months old that had mike skillern as the vice president of science technology and steve sloat as the ceo...........so the scam job can not work here....mike did not start this company and was not involved in the beginning of the research......now if this company is a scam. then it would have been with steve in charge........ now,steve is the same guy that has given information on mike skillern past.....and if he is calling cygs shaky,,,,,isnt he saying that he as the ceo was pulling a scam..........or do we have one bitter person who had a young ,who knows(let say in the business world,back stabber) still his job and company from him......mike past can not play in cygs.... he is not the creator or pioneer here.....

To: Jeffrey S. Mitchell who wrote (2852)	8/17/1998 11:17:00 AM
From: Graham Marshman	Respond to of 4028

Jeffrey, The answers to your questions obviously go beyond CYGS claims. They would be better posed to the company, but if you're interested in my personal opinion, I've given some below: Graham ---- repost with comments------> Graham, good to see someone sticking to the science here. I have a few questions: 1. What other cell lines will the vector work on? I suspect they should at least already have nailed down Cos-7, but what is the timetable for the others? G: Only one confirmed demonstrated is HeLa (human pituitary based.) The next ones targetted are: Cos-7 - monkey kidney - as you suggest important due to its popularity as a cell line for testing with well understood correlation to human performance. U-251 - human brain - not a popular test line. My assumption is that this must be driven by a possible specific alliance or project. Time scale for these last two is unknown. 2. What type of applications are we talking about here? a) Anti-cancer, b) telomerase, c) antisense, d) all three G: I would estimate that the first we will see some specific evidence for is antisense delivery. This would obviously require a relationship with a company owning antisense molecule patents. Many of these are in current clinical trials as you must know. Any direct antisense application would require CYGS to acquire/license or develop an antisense molecule and be subject to full FDA routines at their cost. Telomere repair will require considerable further work and full FDA routine again. Applications for telomere repair include anti-aging and (due to telomerase inhibition) possible anti-cancer application. There is other competitive work going on in antisense based telomerase suppression which would be a factor in the development of that application. 3. Has any patent yet been granted? Anyone can file a patent. And even if CYGS has excellent technology, without a patent being granted they run the risk of patent infringement. What they are doing is a very competitive thing, so without a patent, they have no leg to stand on, and as CYGS is betting the farm on this, no CYGS. G: Their statement on the BB covers current position. 4. How close are they to any sort of clinical application? G: Clinical trials could be as close as an alliance with an antisense company. Application will obviously depend on the completion of the FDA due process by that company. 5. When do they expect Dr. Conrad to finally publish on his research, and in what medical journal do they realistically hope to be accepted into? If CYGS truly does have something that will "rock the medical world", then I expect them to say Nature or Scientific American. At the very least, if the technology is "decent", I expect Cell. G: I've never mentioned "world-rocking". I do believe the ability to deliver single strand DNA into targetted cells is unique and valuable. This kind of news would be expected to appear first in a journal such as CELL or similar peer-reviewed journal. Scientific American and other popular press publications are follow-ups. When? I don't know - hoping for soon.